Impact of Routine Angiographic Follow-Up After Percutaneous Coronary Intervention With Drug-Eluting Stents in the SPIRIT III Randomized Trial at Three Years
- 1 July 2012
- journal article
- research article
- Published by Elsevier in The American Journal of Cardiology
- Vol. 110 (1) , 21-29
Abstract
No abstract availableKeywords
Funding Information
- Abbott Vascular
This publication has 15 references indexed in Scilit:
- Predicting Restenosis of Drug-Eluting Stents Placed in Real-World Clinical PracticeCirculation: Cardiovascular Interventions, 2010
- Angiographic Predictors of Recurrent Stent Thrombosis (from the Outcome of PCI for Stent-ThrombosIs MultIcentre STudy [OPTIMIST])The American Journal of Cardiology, 2010
- Drug-Eluting Versus Bare-Metal Stents in Unprotected Left Main Coronary Artery StenosisJACC: Cardiovascular Interventions, 2010
- Benefits of drug-eluting stents as compared to bare metal stent in ST-segment elevation myocardial infarction: Four year results of the PaclitAxel or Sirolimus-Eluting stent vs bare metal stent in primary angiOplasty (PASEO) randomized trialAmerican Heart Journal, 2009
- Safety and Efficacy Update on First-Generation Drug-Eluting StentsThe American Journal of Cardiology, 2008
- Clinical End Points in Coronary Stent TrialsCirculation, 2007
- Impact of Routine Angiographic Follow-Up on the Clinical Benefits of Paclitaxel-Eluting StentsJACC, 2006
- Sirolimus-Eluting Stents versus Standard Stents in Patients with Stenosis in a Native Coronary ArteryNew England Journal of Medicine, 2003
- Long-Term Follow-up after Percutaneous Transluminal Coronary AngioplastyNew England Journal of Medicine, 1987
- TRANSLUMINAL DILATATION OF CORONARY-ARTERY STENOSISThe Lancet, 1978